Professional
Added to YB: 2024-10-07
Pitch date: 2024-10-01
NVO [bullish]
Novo Nordisk A/S
-55.97%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 114.40
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
growth
Protean Select Funds Portfolio Holding: Novo Nordisk A/S
NVO: Recent 20% drawdown despite 20%+ profit growth, buybacks & dividend. Position increased on dips. Rotation from defensives to materials likely cause. Expecting fundamentals to prevail. Q3 expectations reset. CagriSema readout in late Q4 key catalyst. Not expensive despite being Europe's largest company.
Read full article (1 min)